Fludarabine

製品コードS1491 別名:FaraA, Fludarabinum

Fludarabine化学構造

分子量(MW):285.23

Fludarabine is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells.

サイズ 価格(税別)  
JPY 20932.00
JPY 16102.00
JPY 51460.00
JPY 78020.00

カスタマーフィードバック(5)

  • Br J Cancer, 2018, 118(4):509-521. Fludarabine purchased from Selleck.

    ERK signaling regulates STAT1 phosphorylation, and pSTAT1 modulates MHC II expression in the spinal cord under BCP conditions. AG490 (5 μg in 10 μL), Fludarabine (10 μg in 10 μL), or U0126 (5 μg in 10 μL) was intrathecally injected into cancer-bearing rats once a day for 14 days, beginning immediately after carcinoma cell inoculation (n = 3 in each group). (A) Representative western blot showing pSTAT1ser727, total STAT1, pERK42/44, total ERK42/44, CIITA, MHC II RTIB, and b actin protein levels in the spinal cords of BCP rats.

    Brain Behav Immun, 2017, 60:161-173. Fludarabine purchased from Selleck.

  • Imatinib mesylate (IM) in combination of fludarabine phosphate (F-AMP) significantly inhibits Ki67 and c-KIT expression in GIST-T1 tumor xenografts. Tumors were collected on the day after the last treatment and were then subjected to immunohistochemical detection of Ki67 and c-KIT expression. Representative images of immunohistochemical staining of Ki67 and c-KIT in mice tumors.

    Mol Cancer Ther, 2014, 13(10): 2276-87 . Fludarabine purchased from Selleck.

    Normal human KC pretreated with STAT1 inhibitor (fludarabine [10 uM]) or STAT3 inhibitor (STA-21 [2 uM]) for 24 h. The mRNA levels of hBD2 and hBD3 were assessed by qRT-PCR.

    Mol Cell Biol 2014 34(24), 4368-78.. Fludarabine purchased from Selleck.

  • Bacterial infection in IPEC-J2 cells. The invasion and attachment of EHECO157:H7 was increased in the IPEC-J2 cells in the presence of 10 μM fludarabine. Data are expressed as the mean ± SEM (n= 6). Differences between groups were determined by paired samples t-test. *P<0.05 compared with the control.

    Int Immunopharmacol, 2016, 36:199-204.. Fludarabine purchased from Selleck.

製品安全説明書

STAT阻害剤の選択性比較

生物活性

製品説明 Fludarabine is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells.
ターゲット
STAT1 [4]
(Vascular smooth muscle cells)
体外試験

Fludarabine efficiently inhibits the proliferation of RPMI 8226 cells with IC50 of 1.54 μg/mL. The IC50 of Fludarabine against MM.1S and MM.1R cells is 13.48 μg/mL and 33.79 μg/mL, respectively. In contrast, U266 cells are resistant to Fludarabine with IC50 of 222.2 μg/mL. Fludarabine treatment results in increased number of cells in the G1 phase of cell cycle, accompanied with a concomitant reduction of cells at the S phase of cell cycle in a time-dependent manner. Fludarabine induces a cell cycle block and triggers apoptosis in MM cells. Fludarabine triggers time-dependent cleavage of caspase-8, -9, and -3, -7, followed by PARP cleavage. Fludarabine increases expression of Bax in a time-dependent fashion, while the expression of Bak doesn't change. After exposure to Fludarabine for 12 hours, RPMI 8226 cells shows a loss of membrane potential with 61.05% of the cells expressing low fluorescence of rhodamine 123 compared with 8.62% of cells in untreated control. [1] To enhance solubility, Fludarabine is formulated as the monophosphate (F-ara-AMP, fudarabine), which is instantaneously and quantitatively dephosphorylated to the parent nucleoside upon intravenous infusion. Inside the cells rephosphorylation occurs which leads to fuoroadenine arabinoside triphosphate (F-ara-ATP), the major cytotoxic metabolite of F-ara-A. [2] Fludarabine can also induce pro-inflammatory stimulation of monocytic cells, as evaluated by increased expression of ICAM-1 and IL-8 release. [3] Fludarabine does not affect the growth of ovarian cancer cell lines, whereas it induces marked and dose-dependent inhibition of proliferation in melanoma cell lines. [4] Fludarabine induces significant reduction of STAT-1 phosphorylation, whereas it does not change JAK2 activation. Interestingly, Fludarabine does not significantly affect the phosphorylation of these three STAT proteins. Fludarabine (1.5 mg) significantly prevents STAT-1 phosphorylation and also reduces the increased amount of this protein. No significant changes are demonstrated in JAK2 phosphorylation at 2 days, but Fludarabine inhibits JAK2-increased expression at 7 days. Fludarabine specifically inhibits STAT-1 activation without affecting other STAT proteins and consequently diminishes VSMC proliferation. [5]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Jeko-1  NVPod|FPTnWwY4Tpc44hSXO|YYm= MmLvNlAh|ryP NVXxWlhxOjRiaB?= M1zTc4lvcGmkaYTzJIV5eHKnc4Ppc44hd2ZiSVTP MmjYNlU6PDB5MUK=
MV-4-11 MlS0RZBweHSxc3nzJGF{e2G7 NFzV[YszNjVizszN M2jzXFQ5KGh? NGPseVNqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=> NIPSWXkzPTFzMUW4Ny=>
THP-1 MWHBdI9xfG:|aYOgRZN{[Xl? NETj[IszNjVizszN NFvNbZE1QCCq NYfNe4NTcW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk> M2PUclI2OTFzNUiz
MOLM 13 M2HlSGFxd3C2b4Ppd{BCe3OjeR?= NUjJdIZxOi53IN88US=> MXK0PEBp M1exXolv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5 M{SxeVI2OTFzNUiz
KBM3/Bu2506 MWfBdI9xfG:|aYOgRZN{[Xl? M4PkNVIvPSEQvF2= NFj3b2o1QCCq MXzpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= NX\3THViOjVzMUG1PFM>
Nalm-6 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTF6IN88US=> NEj5W2EzPTB4MUGwNS=>
Reh NW\T[Yp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTNyIN88US=> NXTVS3kxOjVyNkGxNFE>
U2937 NYK4d3NrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXPfJRKSzVyPUG2JO69VQ>? NYL5R|IyOjVyNkGxNFE>
Mec-1 NFvQXWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlr4TWM2OO,:nkWwNEDPxE1? NGT6WVgzPTB4MUGwNS=>
RPMI-8226 MmnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHqe2s4UUN3ME21NFAh|ryP NEGyTJEzPTB4MUGwNS=>
Molt-4 M{D1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLKTWM2OD1zOECg{txO MYKyOVA3OTFyMR?=
Nalm-6-FluR MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLvV4dyUUN3ME2yOVAh|ryP NEn2d5czPTB4MUGwNS=>
Raji  NUL5bIZTTnWwY4Tpc44hSXO|YYm= M2Xmb|PDqM7:TR?= MkPxNlQwPDhxN{KgbC=> NVfpTHNwcW6mdXPld{Bi[2O3bYXsZZRqd26|IH;mJJA2OyxicE[zJIFv\CCyN{RCpC=> MkjVNlQ6PDB4OUW=
PBMC M4\xU2Z2dmO2aX;uJGF{e2G7 NWrzOGpsPTBxMUCwJO69VQ>? NG\FR4IzPCCq MlfzSG1UVw>? M4LvcolvcGmkaYTzJHNVSVRzIIDoc5NxcG:{eXzheIlwdg>? NInI[mUzPDlzMUi3Ni=>
MDA-231 NFv1NohHfW6ldHnvckBCe3OjeR?= NWO2d5BPOTByIN88US=> NUTXSotSOjRiaB?= MlvpSG1UVw>? MWjk[YNz\WG|ZYOgTWRQKGW6cILld5Nqd25? M1nIfFI1QTFzOEey
624.38mel  NWSz[nRITnWwY4Tpc44hSXO|YYm= MX21NEDPxE1? MmDyNlQhcA>? M3fvUWROW09? MoXq[IVkemWjc3XzJGlFVyCneIDy[ZN{cW:w M3PPUFI1QTFzOEey
MDA-231 Mn60SpVv[3Srb36gRZN{[Xl? M2KwRlUxNTJyMDFOwG0> M1T2WFI1KGh? MWnEUXNQ MlOybY5pcWKrdIOgTWRQKGGldHn2bZR6KGmwZHXw[Y5l\W62bImgc4YhdVKQQTDs[ZZmdHN? M1z5e|I1QTFzOEey
624.38mel  MmT0SpVv[3Srb36gRZN{[Xl? Mm\nOVAuOjByIN88US=> M3jndlI1KGh? M3jlRWROW09? NF\kZ|NqdmirYnn0d{BKTE9iYXP0bZZqfHliaX7k[ZBmdmSnboTsfUBw\iCvUl7BJIxmfmWucx?= MWeyOFkyOTh5Mh?=
HMECs Mn\3SpVv[3Srb36gRZN{[Xl? Mkn6NVAxyqEQvF5CpC=> MlTRN|bDqGh? MkP6bY5pcWKrdIOgTWZP|rQEoHHu[EBNWFNiaX7keYNm\CCVVFHUNUBxcG:|cHjvdplt[XSrb36gZY5lKEmURkGg[ZhxemW|c3nvci=> NU\ucVlEOjR{MUGzNlc>
HMECs  NXLRSlZsTnWwY4Tpc44hSXO|YYm= NHGxbHUyODEEoN88UeKh MYmzOuKhcA>? M4\SeolvcGmkaYTzJGlHVs7zwrDt[YRq[XSnZDDwbI9{eGixconsZZRqd25ib3[gV3RCXDFiYX7kJHNVSVR|LDDieZQhdm:2IH;mJHNVSVR{ M{CxbFI1OjFzM{K3
BJAB MlXURZBweHSxc3nzJGF{e2G7 M4Dyc|XDqM7:TR?= M{LuU|I1KGh? MmK1bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MlT0NlQxPTdzNEe=
I-83 M1\TO2Fxd3C2b4Ppd{BCe3OjeR?= M17iVFXDqM7:TR?= MUGyOEBp MWLpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MlHuNlQxPTdzNEe=
NALM6 MkP3RZBweHSxc3nzJGF{e2G7 M{jO[|XDqM7:TR?= MmHrNlQhcA>? NITOWnJqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MoD6NlQxPTdzNEe=
DU-145 MnLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUThZXNJOC1zMDFOwIcwdWx? MnLDOFghcMLi MVzpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M4PKclI{PzN2OEG1
Nalm-6 NVLQVllWTnWwY4Tpc44hSXO|YYm= MX:xNOKh|ryP MmrLNU8zNzRiaB?= MVjpcoR2[2W|IHH1eI9xcGGpeR?= MVqyN|Y5OTJ{Mx?=
Reh MWXGeY5kfGmxbjDBd5NigQ>? NH;sNXgyOMLizszN NYT6[2N[OS9{L{SgbC=> MXvpcoR2[2W|IHH1eI9xcGGpeR?= MmXmNlM3QDF{MkO=
Nalm-6 NF73fGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIKyWmtKSzVyIPMIwFEx6oDLzszN NF\pV48zOzZ6MUKyNy=>
Reh M{HNUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxKOLKvEGw5qCK|ryP MlS1NlM3QDF{MkO=
HEC1A MnGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYCxNFAuPTByIN88US=> M4jofVI1KGh? M{DyeYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz Mo\UNlM2QTV4OUe=
AN3CA M3viU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;rTVExOC13MECg{txO MknpNlQhcA>? MVXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MXeyN|U6PTZ7Nx?=
HEC50B MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHP1eJQyODBvNUCwJO69VQ>? MkPJNlQhcA>? MkPFbY5pcWKrdIOgZ4VtdCCpcn;3eIghe2yrZ3j0cJk> MYqyN|U6PTZ7Nx?=
HEC1A NVG4fWNiSXCxcITvd4l{KEG|c3H5 NUHMU|kxOjBxMUCwJO69VQ>? M3\OVlI1KGh? MVvpcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NIHHTm4zOzV7NU[5Oy=>
AN3CA MkfURZBweHSxc3nzJGF{e2G7 NYmxSll[OjBxMUCwJO69VQ>? M1XHbVI1KGh? NWPXV4U2cW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> Mn;3NlM2QTV4OUe=
HEC50B NYnzbYFQSXCxcITvd4l{KEG|c3H5 M1HObVIxNzFyMDFOwG0> MmTmNlQhcA>? MVrpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= MWqyN|U6PTZ7Nx?=
EHEB MojnRZBweHSxc3nzJGF{e2G7 NIXIbFc1OCEQvF2= M1;pbVI1KGh? MWrpcoR2[2W|IHHwc5B1d3Orcx?= NUjX[3VtOjN2OUewO|U>
A549 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTF3LkhCtVIvQCEEtV2= MY[yN|M4PzF7Mh?=
A549 GAPDH-deficient M3SzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnCTWM2OD1zOD61xtEzNjNiwsXN Mlf1NlM{PzdzOUK=
CLL  NITm[ohCeG:ydH;zbZMhSXO|YYm= NVjibZA6OTBizszNxsA> MoDHNlQuQTZiaB?= NYDjTFBRcW6mdXPld{BieG:ydH;0bYMh[2WubDDk[YF1cA>? M4XLUFIzOjB5Nki2
MEC1 MUnBdI9xfG:|aYOgRZN{[Xl? MV:xNFDDqM7:TR?= MmD2O|IhcA>? NF6zcXdqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7 NFnXNmwzOjF|Mkm3Ny=>
U937  NUiyd3JxSXCxcITvd4l{KEG|c3H5 NXjK[GtQOC56IN88US=> M2W3clQuPDhiaB?= NWSzbJpncW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk> NUnYTIo{OjJyN{S3NFA>
U937  Mn2xRZBweHSxc3nzJGF{e2G7 MmSwNUDPxE1? NUizOYtjQTZiaB?= Mn;FbY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= MXqyNlAzOzV{Mx?=
Daudi M13qZmFxd3C2b4Ppd{BCe3OjeR?= MUKyNEDPxE1? NEfNPJQ6PiCq MX\pcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= MYWyNlAzOzV{Mx?=
J45.01 MX7BdI9xfG:|aYOgRZN{[Xl? MoexNUDPxE1? MoDmPVYhcA>? NFHWbWdqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=> MV[yNlAzOzV{Mx?=
RPMI 8226 NXTxNHo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{G0[GlEPTB;MkWuPeKhyrIEoEOuO{DPxE1? NInrOoQzOTl2OEK2OC=>
CEM MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTJwNNMgxtHDqDBwNDFOwG0> NXq1T|dwOjF7NEiyOlQ>
Raji M3LxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHQNnlKSzVyPUCuOFfDqMLzwrCwMlA1KM7:TR?= MXWyNVk1QDJ4NB?=
U937 Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjRTWM2OD1yLkK0xsDDucLiMD6wOEDPxE1? NVHLcndFOjF7NEiyOlQ>
K562 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPlZWlKSzVyPUCuOFTDqMLzwrCwMlA2KM7:TR?= MViyNVk1QDJ4NB?=
NALM-6 MoDtRZBweHSxc3nzJGF{e2G7 MUmxNEDPxE4EoB?= NVSyU246OjRiaB?= M2njWolv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3zp[4h1dHl? NWrOfZZHOjF4OUmzPFM>
JMV-3 MVzBdI9xfG:|aYOgRZN{[Xl? NX;HPIJWOTBizszNxsA> MVSyOEBp NFzkRnRqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPsbYdpfGy7 MUCyNVY6QTN6Mx?=
EHEB NVTwWIJiTnWwY4Tpc44hSXO|YYm= M1fyeVUuPTBizszN NGq2eZgzPCCq NIq0eYhl\WO{ZXHz[ZMheDJzIHX4dJJme3Orb36gd4lodmmoaXPhcpRtgQ>? MVSyNVE3QDN7MR?=
JVM-2  M1jBPWZ2dmO2aX;uJGF{e2G7 NHzUZnY{OCEQvF2= MlLBNlQhcA>? MknS[IVkemWjc3XzJJAzOSCneIDy[ZN{cW:w M4fLPFIyOTZ6M{mx
KBM3/Bu2506 NF2yWFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;Tc2lEOjB;MD62O{DDvU1? M4fEW|IxQTN|NUC5
KBM3/Bu2506 NXr4U5FxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlntNE43KM7:TR?= NWHJTY9KOjRiaB?= Mn\zbY5kemWjc3XzJJRp\SClZXzsJIZz[WO2aX;uJIlvKFNvcHjhd4U> NFnieXQzODl|M{WwPS=>
MDA-MB-231 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvYW3VmUUN3ME20MlAh|ryP NFnXengzODR2N{O5NC=>
MCF-7 MoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTF3LkCg{txO NGTHbmYzODR2N{O5NC=>
HLE-B3  NGKx[ZJHfW6ldHnvckBCe3OjeR?= MYWyOUDPxE1? NEfLbZo1QCCq MorzZoxw[2u|IFnGUk3Pu+LCk3nu[JVk\WRiU2TBWFEheGixc4Doc5J6dGG2aX;uJIFv\CCLRF:g[ZhxemW|c3nvci=> NXmwdXpPOjB2M{WxOVg>
K562 M37Wd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVS3NkBp NWX5fllGUUN3ME2zMlMhdk1? MX2yNFMxPzF7OB?=
BW-225 M1;5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1v2TGlEOjB;MT6zO{DEnzFy4pkSPOKh|ryPwrC= M1vCW|E5PjZzM{iw
OH-65 M17r[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|IxRTFwM{egx7cyOOLKkklCpO69VcLi MUOxPFY3OTN6MB?=
GR-145 MlvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\5V3hKSzJyPUKuO|Qhy5diMUFijLI5KCEQvF5CpC=> NV;PVHJ1OTh4NkGzPFA>
A549 NEPSfWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIT1UFBKSzJyPUWuOFghy5diMUFijLI5KM7:TdMg M1vWSFE5PjZzM{iw
CaSki  NIjhO4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnL0TWMzOD1zLkO3JOOYKDFy4pkSO{DPxE4EoB?= M1;pVFE5PjZzM{iw
ZMK-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|IxRTFwM{egx7chOTEkiKK2JO69VcLi M{P5blE5PjZzM{iw
SKW6.4 NV;RR5dLSXCxcITvd4l{KEG|c3H5 NX72cmpyOC5yMT2xNEDPxE1? NF25TWszPC92ODDo NG\pc2FqdmS3Y3XzJINmdGxiZHXheIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT2g[IVx\W6mZX70JI1idm6nch?= M{CxNVE5ODl{M{Sw
RPMI 8226 NIPycXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoSwNlQhcA>? NIXU[|dKSzVyPUGuOVTDqM7:TR?= MkXENVc6PzZzOE[=
MM.1S MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUeyPWZsPDhiaB?= NWDrboVpUUN3ME2xN{41QMLizszN NHWwZWoyPzl5NkG4Oi=>
MM.1R MknuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjCZ4tIPDhiaB?= NGjRWWVKSzVyPUOzMlc6KM7:TR?= MlTnNVc6PzZzOE[=
U937 NFrpW|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nHOWlEPTB;MzyyNFAhyrFiNU[wJI5O MWSxOVk{ODN4MR?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Tumors treated with PBS grow rapidly to approx-imately 10-fold their initial volume in 25 day, whereas, the tumors in the Fludarabine at 40 mg/kg increase less than 5-fold. A significant antitumor effect of 40 mg/kg Fludarabine on RPMI8226 tumor growth is demonstrated. RPMI8226 tumors treated with 40 mg/kg Fludarabine at day 10 increase apoptotic nuclei. Fludarabine is effective in suppressing RPMI8226 myeloma xenografts in SCID mice. [1]

お薦めの試験操作(参考用のみ)

細胞試験:

[1]

+ 展開
  • 細胞株: Dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines
  • 濃度: 2 μg/mL
  • 反応時間: 24 hours
  • 実験の流れ:

    After treated with Fludarabine or control, dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines (5 × 105 cells) are washed twice in phosphate-buffered saline (PBS) and fixed with 70% ice-cold ethanol, then centrifuged and suspended in PBS containing 100 μg/mL RNase A. After incubated for 30 minutes at 37 ºC, samples are resuspended in 25 μg/mL propidium iodide. Flow cytometry is performed on a FACSCalibur automated system. Apoptosis is determined by Annexin V-FITC apoptosis detection kit, according to the manufacturer's instructions. For TUNEL (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling) assay, cells are analyzed by flow cytometry using the in situ cell death detection kit.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Severe combined immunodeficient (SCID) mice bearing RPMI 8226 cells
  • 製剤: PBS
  • 投薬量: 40 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 57 mg/mL (199.83 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
30% propylene glycol, 5% Tween 80, 65% D5W
混合させたのち直ちに使用することを推奨します。
30 mg/mL (suspension)

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 285.23
化学式

C10H12FN5O4

CAS No. 21679-14-1
保管
in solvent
別名 FaraA, Fludarabinum

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03579888 Not yet recruiting Acute Lymphoblastic Leukemia|Blasts More Than 5 Percent of Bone Marrow Nucleated Cells|Blasts More Than 5 Percent of Peripheral Blood White Cells|CD19 Positive|Chronic Lymphocytic Leukemia|Minimal Residual Disease|Non-Hodgkin Lymphoma|Small Lymphocytic Lymphoma M.D. Anderson Cancer Center|Ziopharm Oncology|Precigen Inc December 2019 Phase 1
NCT03690011 Not yet recruiting T-cell Acute Lymphoblastic Leukemia|T-cell Acute Lymphoblastic Lymphoma|T-non-Hodgkin Lymphoma Baylor College of Medicine|The Methodist Hospital System|Texas Children''s Hospital|Center for Cell and Gene Therapy Baylor College of Medicine March 1 2019 Phase 1
NCT02905188 Not yet recruiting Hepatocellular Carcinoma Baylor College of Medicine|Center for Cell and Gene Therapy Baylor College of Medicine|The Methodist Hospital System March 2019 Phase 1
NCT03697824 Not yet recruiting Neoplasms GlaxoSmithKline|Merck Sharp & Dohme Corp. February 25 2019 Phase 2
NCT03622788 Not yet recruiting Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Acute Myeloid Leukemia in Remission|Aplastic Anemia|Bone Marrow Failure|Chronic Lymphocytic Leukemia|Chronic Myelogenous Leukemia BCR-ABL1 Positive|Donor|Follicular Lymphoma|Hematopoietic Cell Transplantation Recipient|Hodgkin Lymphoma|Mantle Cell Lymphoma|Myelodysplastic Syndrome|Myeloproliferative Neoplasm|Near Complete Response of Multiple Myeloma or Plasma Cell Leukemia|Non-Hodgkin Lymphoma|Partial Response of Multiple Myeloma or Plasma Cell Leukemia|Plasma Cell Myeloma M.D. Anderson Cancer Center|National Cancer Institute (NCI) December 31 2018 Phase 1|Phase 2
NCT03635632 Not yet recruiting Relapsed Neuroblastoma|Refractory Neuroblastoma Baylor College of Medicine|Texas Children''s Hospital|Center for Cell and Gene Therapy Baylor College of Medicine December 2018 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    how to re-suspend and deliver the inhibitor for in vivo experiments?

  • 回答:

    For S1491, Fludarabine, we tested a vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W that you can resuspend the compound in at up to 30mg/ml. It's a suspension and can only be given via oral gavage.

STATシグナル伝達経路

相関STAT製品

Tags: Fludarabineを買う | Fludarabine ic50 | Fludarabine供給者 | Fludarabineを購入する | Fludarabine費用 | Fludarabine生産者 | オーダーFludarabine | Fludarabine化学構造 | Fludarabine分子量 | Fludarabine代理店
×

春節(旧正月)休暇に伴う納期遅延のお知らせ
上海工場が春節休業となるため、輸入が必要な製品の納期が通常より2週間ほど遅れます。
1月25日までにご注文いただきました製品は通常通り出荷させていただきます。1月28日-2月8日にご注文いただいた製品は2月19日以降の出荷となります。ご不便をおかけいたしますが、何卒ご理解くださいますようお願い申し上げます。

×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID